Stem cell trial shows promise for type 2 diabetes

11/9/2011 | Australian Life Scientist

Mesoblast's mesenchymal precursor cells helped maintain lower fasting glucose levels in nonhuman primates with type 2 diabetes over eight weeks, the company announced. MPC-treated primates also had significant reductions in circulating C-reactive protein, a sign of cardiovascular disease risk, experts said.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR